Strides Pharma Science Limited (STAR) - Net Assets

Latest as of March 2026: Rs31.49 Billion INR ≈ $340.59 Million USD

Based on the latest financial reports, Strides Pharma Science Limited (STAR) has net assets worth Rs31.49 Billion INR (≈ $340.59 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs69.27 Billion ≈ $749.15 Million USD) and total liabilities (Rs37.78 Billion ≈ $408.57 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Strides Pharma Science Limited PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs31.49 Billion
% of Total Assets	45.46%
Annual Growth Rate	13.57%
5-Year Change	32.14%
10-Year Change	9.56%
Growth Volatility	45.72

Strides Pharma Science Limited - Net Assets Trend (2005–2026)

This chart illustrates how Strides Pharma Science Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Strides Pharma Science Limited (STAR) total market value.

Annual Net Assets for Strides Pharma Science Limited (2005–2026)

The table below shows the annual net assets of Strides Pharma Science Limited from 2005 to 2026. Also explore how fast is Strides Pharma Science Limited growing its equity to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2026-03-31	Rs31.49 Billion ≈ $340.59 Million	+21.76%
2025-03-31	Rs25.86 Billion ≈ $279.72 Million	+24.85%
2024-03-31	Rs20.72 Billion ≈ $224.05 Million	-4.66%
2023-03-31	Rs21.73 Billion ≈ $234.99 Million	-8.83%
2022-03-31	Rs23.83 Billion ≈ $257.75 Million	-15.31%
2021-03-31	Rs28.14 Billion ≈ $304.32 Million	+8.45%
2020-03-31	Rs25.95 Billion ≈ $280.60 Million	-7.39%
2019-03-31	Rs28.02 Billion ≈ $302.99 Million	+7.38%
2018-03-31	Rs26.09 Billion ≈ $282.18 Million	-9.23%
2017-03-31	Rs28.74 Billion ≈ $310.86 Million	-1.09%
2016-03-31	Rs29.06 Billion ≈ $314.27 Million	+149.73%
2015-03-31	Rs11.64 Billion ≈ $125.84 Million	+7.50%
2014-03-31	Rs10.82 Billion ≈ $117.07 Million	-48.41%
2013-03-31	Rs20.98 Billion ≈ $226.90 Million	+47.97%
2012-03-31	Rs14.18 Billion ≈ $153.34 Million	-8.83%
2011-03-31	Rs15.55 Billion ≈ $168.20 Million	+42.74%
2010-03-31	Rs10.90 Billion ≈ $117.83 Million	+82.91%
2009-03-31	Rs5.96 Billion ≈ $64.42 Million	+102.95%
2008-03-31	Rs2.94 Billion ≈ $31.74 Million	-31.86%
2007-03-31	Rs4.31 Billion ≈ $46.59 Million	+24.30%
2006-03-31	Rs3.47 Billion ≈ $37.48 Million	+59.19%
2005-03-31	Rs2.18 Billion ≈ $23.54 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Strides Pharma Science Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 978247000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2026)

Component	Amount	Percentage
Retained Earnings	Rs9.78 Billion	31.48%
Common Stock	Rs921.73 Million	2.97%
Other Comprehensive Income	Rs5.27 Billion	16.96%
Other Components	Rs15.10 Billion	48.59%
Total Equity	Rs31.08 Billion	100.00%

Strides Pharma Science Limited Competitors by Market Cap

The table below lists competitors of Strides Pharma Science Limited ranked by their market capitalization.

Company	Market Cap
Jastrzebska Spotka Weglowa SA WAR:JSW	$1.22 Billion
Ouster, Inc. Common Stock NASDAQ:OUST	$1.22 Billion
He Bei Cheng De LoLo Co Ltd SHE:000848	$1.22 Billion
Zhejiang Jiahua Energy Chemical Industry Co Ltd SHG:600273	$1.22 Billion
Genusplus Group Ltd AU:GNP	$1.22 Billion
Gold.com, Inc. NYSE:GOLD	$1.21 Billion
Jiangsu Bide Science and Technology Co. Ltd. SHG:605298	$1.21 Billion
Exzeo Group, Inc. NYSE:XZO	$1.21 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Strides Pharma Science Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from 25,518,310,000 to 31,075,650,000, a change of 5,557,340,000 (21.8%).
Net income of 5,561,930,000 contributed positively to equity growth.
Dividend payments of 368,650,000 reduced retained earnings.
New share issuances of 3,860,000 increased equity.
Other comprehensive income increased equity by 357,500,000.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	Rs5.56 Billion	+17.9%
Dividends Paid	Rs368.65 Million	-1.19%
Share Issuances	Rs3.86 Million	+0.01%
Other Comprehensive Income	Rs357.50 Million	+1.15%
Other Changes	Rs2.70 Million	+0.01%
Total Change	Rs-	21.78%

Book Value vs Market Value Analysis

This analysis compares Strides Pharma Science Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.62x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 19.43x to 3.62x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2005-03-31	Rs62.77	Rs1219.80	x
2006-03-31	Rs79.59	Rs1219.80	x
2007-03-31	Rs92.87	Rs1219.80	x
2008-03-31	Rs79.07	Rs1219.80	x
2009-03-31	Rs79.08	Rs1219.80	x
2010-03-31	Rs150.93	Rs1219.80	x
2011-03-31	Rs257.32	Rs1219.80	x
2012-03-31	Rs234.14	Rs1219.80	x
2013-03-31	Rs323.10	Rs1219.80	x
2014-03-31	Rs169.43	Rs1219.80	x
2015-03-31	Rs191.41	Rs1219.80	x
2016-03-31	Rs344.57	Rs1219.80	x
2017-03-31	Rs302.68	Rs1219.80	x
2018-03-31	Rs274.22	Rs1219.80	x
2019-03-31	Rs295.70	Rs1219.80	x
2020-03-31	Rs282.13	Rs1219.80	x
2021-03-31	Rs309.52	Rs1219.80	x
2022-03-31	Rs262.87	Rs1219.80	x
2023-03-31	Rs245.57	Rs1219.80	x
2024-03-31	Rs233.25	Rs1219.80	x
2025-03-31	Rs277.31	Rs1219.80	x
2026-03-31	Rs337.13	Rs1219.80	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Strides Pharma Science Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 17.90%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 11.45%
• Asset Turnover: 0.70x
• Equity Multiplier: 2.23x
Recent ROE (17.90%) is above the historical average (4.48%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2005	16.84%	9.80%	0.66x	2.62x	Rs142.81 Million
2006	15.65%	9.35%	0.56x	3.02x	Rs175.26 Million
2007	10.64%	5.41%	0.61x	3.25x	Rs24.23 Million
2008	-18.12%	-6.91%	0.36x	7.35x	Rs-777.80 Million
2009	25.99%	10.58%	0.44x	5.60x	Rs664.22 Million
2010	13.20%	8.41%	0.40x	3.89x	Rs265.76 Million
2011	9.55%	7.22%	0.38x	3.50x	Rs-58.31 Million
2012	16.37%	8.93%	0.46x	3.98x	Rs873.28 Million
2013	41.76%	38.37%	0.46x	2.37x	Rs6.44 Billion
2014	-52.30%	-52.34%	0.48x	2.08x	Rs-6.27 Billion
2015	0.14%	0.13%	0.48x	2.17x	Rs-1.13 Billion
2016	3.43%	3.43%	0.37x	2.68x	Rs-1.88 Billion
2017	6.69%	6.58%	0.34x	2.99x	Rs-898.37 Million
2018	-1.87%	-1.61%	0.43x	2.67x	Rs-2.91 Billion
2019	1.97%	2.47%	0.26x	3.02x	Rs-2.13 Billion
2020	0.96%	0.90%	0.44x	2.43x	Rs-2.29 Billion
2021	9.17%	7.76%	0.47x	2.53x	Rs-231.65 Million
2022	-19.51%	-15.05%	0.44x	2.96x	Rs-6.96 Billion
2023	-10.00%	-6.03%	0.55x	3.00x	Rs-4.42 Billion
2024	-5.66%	-3.14%	0.66x	2.75x	Rs-3.33 Billion
2025	15.88%	9.06%	0.74x	2.37x	Rs1.50 Billion
2026	17.90%	11.45%	0.70x	2.23x	Rs2.45 Billion

Industry Comparison

This section compares Strides Pharma Science Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $55,732,551,119
Average return on equity (ROE) among peers: 12.78%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Strides Pharma Science Limited (STAR)	Rs31.49 Billion	16.84%	1.20x	$1.22 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$354.09 Million	3.07%	2.25x	$31.32 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.00 Billion	13.75%	2.66x	$426.21 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$2.31 Million	-8.08%	0.08x	$804.25 Million
Abbott India Limited (ABBOTINDIA)	$36.99 Billion	32.48%	0.40x	$6.27 Billion
Ajanta Pharma Limited (AJANTPHARM)	$29.96 Billion	21.83%	0.26x	$4.81 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$33.31 Billion	7.66%	0.64x	$1.30 Billion
Alkem Laboratories Limited (ALKEM)	$75.58 Billion	20.97%	0.52x	$7.07 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$1.29 Billion	15.52%	0.29x	$154.33 Million
Alembic Pharmaceuticals Limited (APLLTD)	$52.38 Billion	9.95%	0.36x	$1.80 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$326.47 Billion	10.68%	0.52x	$10.79 Billion

About Strides Pharma Science Limited

NSE:STAR India Drug Manufacturers - Specialty & Generic

Market Cap

$1.22 Billion

Rs112.43 Billion INR

Market Cap Rank

#8114 Global

#403 in India

Share Price

Rs1219.80

Change (1 day)

+1.63%

52-Week Range

Rs793.55 - Rs1219.80

All Time High

Rs1643.30